Early trial tests re-engineered immune cells to battle multiple cancers
NCT ID NCT05035407
Summary
This early-phase study tested the safety of a new cell therapy for adults with advanced cancers that have a specific marker called KK-LC-1. Doctors collected a patient's own immune cells, modified them in a lab to better recognize and attack cancer cells, and then infused them back into the patient after a course of chemotherapy. The main goal was to find a safe dose and understand the side effects of this experimental treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KITA-KYUSHU LUNG CANCER ANTIGEN 1, HUMAN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.